Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the Dow Jones Industrial Average ( ^DJI) trading up 16 points (0.1%) at 16,738 as of Wednesday, June 4, 2014, 3:55 PM ET. The NYSE advances/declines ratio sits at 1,467 issues advancing vs. 1,547 declining with 149 unchanged.

The Drugs industry as a whole closed the day up 0.6% versus the S&P 500, which was up 0.2%. Top gainers within the Drugs industry included XTL Biopharmaceuticals ( XTLB), up 5.4%, Oragenics ( OGEN), up 2.0%, Codexis ( CDXS), up 2.1%, Transcept Pharmaceuticals ( TSPT), up 10.2% and Telik ( TELK), up 1.6%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Codexis ( CDXS) is one of the companies that pushed the Drugs industry higher today. Codexis was up $0.03 (2.1%) to $1.45 on light volume. Throughout the day, 25,701 shares of Codexis exchanged hands as compared to its average daily volume of 60,100 shares. The stock ranged in a price between $1.39-$1.45 after having opened the day at $1.41 as compared to the previous trading day's close of $1.42.

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. Codexis has a market cap of $55.3 million and is part of the health care sector. Shares are up 2.1% year-to-date as of the close of trading on Tuesday. Currently there are no analysts who rate Codexis a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Codexis as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on CDXS go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Chemicals industry and the overall market, CODEXIS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • CDXS's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 40.68%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The revenue fell significantly faster than the industry average of 11.3%. Since the same quarter one year prior, revenues fell by 38.4%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • CODEXIS INC has improved earnings per share by 32.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CODEXIS INC reported poor results of -$1.08 versus -$0.83 in the prior year. This year, the market expects an improvement in earnings (-$0.51 versus -$1.08).
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Chemicals industry average. The net income increased by 33.8% when compared to the same quarter one year prior, rising from -$9.62 million to -$6.38 million.

You can view the full analysis from the report here: Codexis Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Oragenics ( OGEN) was up $0.04 (2.0%) to $2.00 on light volume. Throughout the day, 1,776 shares of Oragenics exchanged hands as compared to its average daily volume of 30,300 shares. The stock ranged in a price between $1.96-$2.00 after having opened the day at $1.96 as compared to the previous trading day's close of $1.96.

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $69.0 million and is part of the health care sector. Shares are down 32.0% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates Oragenics a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Oragenics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on OGEN go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 54.9% when compared to the same quarter one year ago, falling from -$1.99 million to -$3.08 million.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 35.65%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 28.57% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • ORAGENICS INC's earnings per share declined by 28.6% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ORAGENICS INC continued to lose money by earning -$0.57 versus -$0.95 in the prior year. This year, the market expects an improvement in earnings (-$0.37 versus -$0.57).
  • The gross profit margin for ORAGENICS INC is currently very high, coming in at 84.60%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -708.04% is in-line with the industry average.

You can view the full analysis from the report here: Oragenics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

XTL Biopharmaceuticals ( XTLB) was another company that pushed the Drugs industry higher today. XTL Biopharmaceuticals was up $0.15 (5.4%) to $2.95 on light volume. Throughout the day, 5,980 shares of XTL Biopharmaceuticals exchanged hands as compared to its average daily volume of 10,000 shares. The stock ranged in a price between $2.49-$2.95 after having opened the day at $2.49 as compared to the previous trading day's close of $2.80.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. XTL Biopharmaceuticals has a market cap of $32.6 million and is part of the health care sector. Shares are down 3.5% year-to-date as of the close of trading on Tuesday. Currently there are no analysts who rate XTL Biopharmaceuticals a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates XTL Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on XTLB go as follows:

  • XTL BIOPHARMACEUTICALS has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, XTL BIOPHARMACEUTICALS reported poor results of -$0.22 versus -$0.13 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 288.5% when compared to the same quarter one year ago, falling from -$0.30 million to -$1.15 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, XTL BIOPHARMACEUTICALS's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has decreased to -$0.52 million or 27.45% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 52.78%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 233.33% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here: XTL Biopharmaceuticals Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.